WO2005025590A3 - Utilisation d'un produit proteique dg280 dans la prevention et le traitement de troubles metaboliques - Google Patents

Utilisation d'un produit proteique dg280 dans la prevention et le traitement de troubles metaboliques Download PDF

Info

Publication number
WO2005025590A3
WO2005025590A3 PCT/EP2004/010271 EP2004010271W WO2005025590A3 WO 2005025590 A3 WO2005025590 A3 WO 2005025590A3 EP 2004010271 W EP2004010271 W EP 2004010271W WO 2005025590 A3 WO2005025590 A3 WO 2005025590A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
protein product
metabolic disorders
treating metabolic
disorders
Prior art date
Application number
PCT/EP2004/010271
Other languages
English (en)
Other versions
WO2005025590A2 (fr
Inventor
Tri Nguyen
Original Assignee
Develogen Ag
Tri Nguyen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag, Tri Nguyen filed Critical Develogen Ag
Publication of WO2005025590A2 publication Critical patent/WO2005025590A2/fr
Publication of WO2005025590A3 publication Critical patent/WO2005025590A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)

Abstract

La présente invention porte sur de nouvelles utilisations de protéines de régulation de l'homéostasie énergétique et de polynucléotides codant ces protéines dans le diagnostic, l'étude, la prévention et le traitement de maladies et de troubles métaboliques.
PCT/EP2004/010271 2003-09-15 2004-09-14 Utilisation d'un produit proteique dg280 dans la prevention et le traitement de troubles metaboliques WO2005025590A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03020861.5 2003-09-15
EP03020861 2003-09-15

Publications (2)

Publication Number Publication Date
WO2005025590A2 WO2005025590A2 (fr) 2005-03-24
WO2005025590A3 true WO2005025590A3 (fr) 2005-11-03

Family

ID=34306765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/010271 WO2005025590A2 (fr) 2003-09-15 2004-09-14 Utilisation d'un produit proteique dg280 dans la prevention et le traitement de troubles metaboliques

Country Status (1)

Country Link
WO (1) WO2005025590A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054325A1 (fr) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Frp humaine et fragments de cette derniere et leurs utilisations
EP1001023A2 (fr) * 1998-09-09 2000-05-17 Smithkline Beecham Plc Frizzled-4, un possible récepteur pour Wnt
WO2003004045A2 (fr) * 2001-07-05 2003-01-16 Xenon Genetics, Inc. Procedes permettant d'identifier des agents therapeutiques pour traiter des maladies impliquant des polypeptides wnt et des recepteurs wnt
WO2003005034A2 (fr) * 2001-07-05 2003-01-16 Xenon Genetics, Inc. Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene
WO2004020465A2 (fr) * 2002-09-02 2004-03-11 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteines intervenant dans la regulation de l'homeostasie energetique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054325A1 (fr) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Frp humaine et fragments de cette derniere et leurs utilisations
EP1001023A2 (fr) * 1998-09-09 2000-05-17 Smithkline Beecham Plc Frizzled-4, un possible récepteur pour Wnt
WO2003004045A2 (fr) * 2001-07-05 2003-01-16 Xenon Genetics, Inc. Procedes permettant d'identifier des agents therapeutiques pour traiter des maladies impliquant des polypeptides wnt et des recepteurs wnt
WO2003005034A2 (fr) * 2001-07-05 2003-01-16 Xenon Genetics, Inc. Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene
WO2004020465A2 (fr) * 2002-09-02 2004-03-11 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteines intervenant dans la regulation de l'homeostasie energetique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENNETT CHRISTINA N ET AL: "Regulation of Wnt signaling during adipogenesis", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 34, 23 August 2002 (2002-08-23), pages 30998 - 31004, XP002282969, ISSN: 0021-9258 *
ROSS SARAH E ET AL: "Inhibition of adipogenesis by Wnt signaling", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 289, no. 5481, 11 August 2000 (2000-08-11), pages 950 - 953, XP002282971, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
WO2005025590A2 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2007021886A3 (fr) Compositions de memapsine 2 tronquee et traitements associes
WO2006048450A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
EP1636160A4 (fr) Nouveaux agents therapeutiques permettant de traiter le cancer, les maladies metaboliques et les affections cutanees
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
WO2003005880A3 (fr) Les peptides 'replikines' et leurs utilisations
WO2004007667A3 (fr) Polynucleotide et polypeptide de regulation du metabolisme des graisses et leurs utilisations
WO2004056768A3 (fr) Utilisation de 2,5-diamidoindoles substitues pour le traitement de maladies urologiques
WO2003055980A3 (fr) Molecules du type il-17 et utilisations associees
WO2004035082A3 (fr) Proteines impliquees dans la regulation de l'homeostasie energetique
WO2005025590A3 (fr) Utilisation d'un produit proteique dg280 dans la prevention et le traitement de troubles metaboliques
WO2003026566A3 (fr) Atlastine
WO2005067957A3 (fr) Utilisation d'un produit proteique dg47 pour la prevention et le traitement de troubles metaboliques
WO2003092715A3 (fr) Proteines impliquees dans la regulation de l'homeostasie energetique
WO2004020465A3 (fr) Proteines intervenant dans la regulation de l'homeostasie energetique
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
WO2004064856A3 (fr) Proteines impliquees dans la regulation de l'homeostasie energetique
WO2004047855A3 (fr) Proteines impliquees dans la regulation de l'homeostasie de l'energie
WO2004016641A3 (fr) Proteines intervenant dans la regulation de l'homeostase energetique
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2004054601A3 (fr) Proteines impliquees dans l'homeostase energetique
WO2003084566A3 (fr) Proteines impliquees dans la regulation de homeostasie energetique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase